Finn
LQDA Biotechnology · Rare disease · Commercial-stage biotech · Speculative · Thesis updated November 15, 2026

YUTREPIA sales surge as patent litigation is permanently settled

01 Running thesis

From courtroom drama to a pure execution play

Liquidia has transitioned from a high-stakes litigation story to a pure commercial execution story. The dominant near-term overhang, the United Therapeutics patent litigation, has been fully resolved via a settlement. This secures YUTREPIA's future without ongoing royalties.

YUTREPIA continues its massive commercial ramp, posting $222.7 million in third-quarter net sales in 2026. The bull case is anchored by rapid market share gains in the PAH segment and a deep pipeline of clinical trials to expand into massive new markets.

Bear concerns are now restricted to financial execution and competition. The company must navigate a $380 million cash settlement payment through April 2027 while fending off aggressive competitor marketing tactics.

Nov 2026▲Q3 2026 earnings revealed the permanent settlement of the United Therapeutics patent litigation. YUTREPIA sales surged to $222.7 million, shifting the story to commercial execution and managing the $380 million cash settlement payment.
Aug 2026▲Q2 2026 earnings showed YUTREPIA capturing nearly 30 percent of the inhaled market with $170.4 million in net sales, prompting 2027 guidance above $1 billion.
May 2026→Management confirmed the depletion of zero-cost YUTREPIA inventory, meaning future margins will face full manufacturing costs. The company also announced plans to initiate trials for massive lifecycle expansion opportunities like PH-COPD.
Aug 2025▲Liquidia's Q2 2025 filing confirmed FDA approval, U.S. launch, and $6.5 million of first-month YUTREPIA net product sales. Management also removed the prior near-term going-concern warning based on current plans.
May 2025▲A key United Therapeutics challenge to adding PH-ILD to the YUTREPIA label was dismissed. Management also said launch product could enter the channel within 2 to 3 weeks of approval.
May 2025→The Q1 2025 filing set a May 24, 2025 PDUFA goal date for YUTREPIA, creating a clear near-term catalyst. The same filing still warned that cash would not fund the company for a year without external financing or YUTREPIA sales.
Mar 2025▼The 2024 10-K raised the risk profile with a going-concern warning, higher legal pressure, and limits on Treprostinil Injection from the discontinued CADD-MS 3 pump.
02 Business model

Pure commercial execution and funding a pipeline

Liquidia makes money primarily through direct U.S. sales of YUTREPIA, an inhaled dry powder form of treprostinil. A small secondary source is a profit-sharing agreement with Sandoz for a generic Treprostinil Injection.

Following a permanent settlement with United Therapeutics, YUTREPIA's market availability is fully secured with no ongoing royalties owed. This shifts the model purely to commercial execution and scaling.

The financial model is facing a new reality on margins. The company has sold through all its pre-approval zero-cost inventory. Future product sales will now reflect the full cost of manufacturing, which will compress gross margins even as top-line revenue scales.

03 Product portfolio

Treprostinil, several forms

Growth engine

YUTREPIA for PAH and PH-ILD

Approved and commercialized for pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease.

Option

YUTREPIA lifecycle expansion

The company is planning new clinical studies for PH-COPD, IPF, progressive pulmonary fibrosis, and systemic sclerosis.

Steady

Treprostinil Injection

A generic version of Remodulin sold with Sandoz. Growth is severely limited because the required CADD-MS 3 infusion pump is discontinued.

Option

L606

An investigational twice-daily inhaled liposomal treprostinil product. It is currently in a global pivotal study for PH-ILD.

04 Business segments

Revenue is dominated by YUTREPIA

YUTREPIA product sales99%growing fast
Sandoz service revenue1%declining

Liquidia does not present classic business segments. This mix relies on reported revenue lines, reflecting the massive recent scale-up of YUTREPIA product sales against constrained Sandoz service revenue in late 2026.

05 Risk factors

What could break the story

Massive settlement obligation

High impact · High odds

The United Therapeutics litigation is settled, but Liquidia now faces a massive one-time charge. Over $380 million is payable in cash through April 2027, putting intense pressure on the balance sheet.

We watchWatch cash flow statements and any announcements of external financing to cover the payments.

Gross margin compression

Medium impact · High odds

Liquidia has sold through its pre-approval zero-cost inventory for YUTREPIA. Future sales will carry the full weight of manufacturing costs, reducing gross margins.

We watchWatch quarterly cost of goods sold and management commentary on gross margin stabilization.

Growth sustainability

High impact · Medium odds

The financial plan depends heavily on YUTREPIA becoming a massive commercial success. If prescriptions or insurance coverage fall short of the $1 billion target for 2027, the stock will suffer.

We watchWatch quarterly YUTREPIA net product sales and new patient starts.

Market competition

Medium impact · High odds

YUTREPIA competes with established inhaled therapies like Tyvaso and new drug classes like Merck's Winrevair. Liquidia needs to convince doctors to switch patients to its dry powder inhaler.

We watchWatch market share comments and any signs that competing therapies are capturing new patient growth.
06 Quick answers

In one breath

What does Liquidia sell?

Liquidia sells YUTREPIA, an inhaled dry powder form of treprostinil for PAH and PH-ILD. It also earns service revenue from promoting Sandoz's generic Treprostinil Injection in the U.S.

Why is Liquidia considered speculative?

The company relies almost entirely on one newly launched drug and faces a massive cash settlement payment. While YUTREPIA is generating significant revenue, any stumble in sales could strain the balance sheet.

What is PRINT technology?

PRINT is Liquidia's particle engineering technology. It is used to make drug particles with a uniform size and shape, allowing medicine to reach deep into the lungs.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Liquidia Q3 2026 earnings transcript
  2. Liquidia Q2 2026 earnings transcript
  3. Liquidia Q1 2026 Form 10-Q
  4. Liquidia Q2 2025 Form 10-Q
  5. Liquidia 2024 Form 10-K
08 Explore the industry

Comparable Biotechnology companies

Companies near Liquidia Corporation in Finn's Biotechnology industry ranking.

Get started with Finn today